Pyrrolotriazine kinase inhibitors
US6951859B2 · kind B2 · utility
19Cited by
0References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 4, 2003 |
| Grant date | Oct 4, 2005 |
| Priority date | — |
| Expiry date | Aug 4, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.